Prenatal Vitamins

Pregnancy

The strongest pregnancy guidance concerns folic acid and the time around conception. CDC recommends 400 micrograms daily for people who can become pregnant, and ACOG describes a prenatal vitamin with at least 400 micrograms before conception and in early pregnancy. ACOG describes a separate 4 mg folic-acid dose for a prior pregnancy affected by a neural-tube defect; this is a special-history recommendation, not the usual amount in a prenatal formula. Primary studies support the folic-acid claim, not every ingredient in every product. In a 1992 Hungarian randomized trial, a multivitamin with 0.8 mg folic acid was linked to 0 neural-tube defects among 2,104 pregnancies with known outcomes, compared with 6 among 2,052 in the trace-element group. In the 1993-1995 China public-health program, 400 micrograms folic acid was offered before and during early pregnancy; among women registering before their last menstrual period, rates were 4.8 versus 1.0 per 1,000 pregnancies in the high-rate region and 1.0 versus 0.6 per 1,000 in the low-rate region. This was a public-health intervention, not a randomized trial. For recurrence prevention, the MRC randomized trial enrolled women with a previous affected pregnancy; among 1,195 completed pregnancies with known outcomes, 6 neural-tube defects occurred in folic-acid groups and 21 in other groups, a 72% protective effect. For multiple-micronutrient supplements, trial results depend on setting and comparator. The 2019 Cochrane review included 20 data-contributing trials and 141,849 women; 19 trials in lower- and middle-income settings compared different multiple-micronutrient supplements with iron with or without folic acid. The pooled risk ratio was 0.88 for low birthweight, 0.92 for small-for-gestational-age birth, and 0.95 for preterm birth, with the preterm confidence interval crossing no effect. The single UK placebo trial found little or no important difference in low birthweight, small-for-gestational-age birth, or preterm birth, but did find less maternal anemia. Its primary report enrolled 402 women and only 39% completed the study. The 2026 Ethiopia cluster trial found mean birthweight 38 g higher in districts assigned multiple micronutrients than in districts assigned iron plus folic acid; this was a program trial in one setting, not a test of every retail prenatal. A 2020 analysis of US label records from 2015 through March 2019 found common folic-acid amounts of 1,000 micrograms in prescription products and 800 micrograms in nonprescription products. These are historical label data, not a current market survey. The EMA PRAC minutes describe a signal for cancer with high-dose folic acid at or above 1 mg. Two observational register studies contributed to that signal. In the 2022 childhood cohort, the absolute risk by age 20 among children of mothers with epilepsy was estimated at 1.4% (95% CI 0.5-3.6) after high-dose exposure and 0.6% (95% CI 0.3-1.1) without exposure; the adjusted hazard ratio was 2.7 (95% CI 1.2-6.3). In the 2025 maternal cohort, high-dose use was associated with overall cancer in women who had given birth, but the estimate attenuated from an adjusted hazard ratio of 1.2 to 1.1 after a six-month lag. These observational associations do not establish cause. EMA said the evidence was insufficient to conclude a potential risk and asked companies to monitor new information. CDC's 2026 page cites 13 randomized trials with about 50,000 people and no increase or decrease in cancer cases, while a 2026 FDA folic-acid oral-solution review reported no new safety findings. Those broader sources do not directly match prescription doses of 1 mg or more during pregnancy, so the high-dose signal is disclosed rather than generalized to every prenatal product.

Breastfeeding

Current guidance adds useful context but is not specific to one product. CDC says a multivitamin may benefit a breastfeeding woman if diet alone does not meet increased needs, and recommends that providers tailor supplement choices. CDC's iodine page reports that the American Thyroid Association and AAP recommend a daily multivitamin or prenatal supplement containing 150 micrograms of iodine during breastfeeding; CDC notes that not all products contain this amount. NIH ODS describes prenatal formulations as variable. A 2025 systematic review included randomized trials of nutrient supplements in pregnant or lactating women and assessed maternal and infant nutrient status or milk composition, but it did not evaluate one standard prenatal formula as a product class. These sources support nutrient-specific and diet-specific guidance, not one effect estimate for every prenatal formula while nursing.

What was tested

The trials studied different ingredients, doses, populations, and comparators. Czeizel and Dudas randomized women planning pregnancy to a multivitamin with 0.8 mg folic acid or a trace-element tablet; pregnancy outcomes were known for 2,104 and 2,052 women, respectively. Berry and colleagues evaluated a Chinese public-health program offering 400 micrograms of folic acid daily before and during the first trimester; it was not randomized. The MRC Vitamin Study tested 4 mg folic acid in women with a prior affected pregnancy, so it supports a specific recurrence-prevention group rather than routine product dosing. The Cochrane pregnancy review pooled varied multiple-micronutrient formulations, mainly in lower- and middle-income countries, and its one UK placebo comparison is not interchangeable with the iron-plus-folic-acid comparisons. The 2026 Ethiopia trial tested a district-level change from iron plus folic acid to multiple micronutrients in routine care. Two 2026 prenatal-formulation trials measured biomarkers rather than clinical birth outcomes: the 5-MTHF versus folic-acid trial randomized 80 people and had 31 completers per group; total folate measures were similar while unmetabolized folic acid differed, and several authors were employed by Ritual. The higher-biotin trial recruited 80 people and had 62 completers; it measured maternal and cord-blood biotin biomarkers, not clinical infant outcomes, and several authors were affiliated with Ritual. Neither biomarker study establishes a clinical benefit for all prenatal products.